These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
1126 related items for PubMed ID: 16815245
1. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Bashshur ZF, Bazarbachi A, Schakal A, Haddad ZA, El Haibi CP, Noureddin BN. Am J Ophthalmol; 2006 Jul; 142(1):1-9. PubMed ID: 16815245 [Abstract] [Full Text] [Related]
7. Intravitreal bevacizumab combined with photodynamic therapy for the treatment of occult choroidal neovascularization associated with serous pigment epithelium detachment in age-related macular degeneration. Ladas ID, Kotsolis AI, Papakostas TD, Rouvas AA, Karagiannis DA, Vergados I. Retina; 2007 Sep; 27(7):891-6. PubMed ID: 17891013 [Abstract] [Full Text] [Related]
8. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study. Bashshur ZF, Haddad ZA, Schakal A, Jaafar RF, Saab M, Noureddin BN. Am J Ophthalmol; 2008 Feb; 145(2):249-256. PubMed ID: 18067876 [Abstract] [Full Text] [Related]
9. Intravitreal bevacizumab for treatment-naïve subfoveal occult choroidal neovascularization in age-related macular degeneration. Furino C, Boscia F, Recchimurzo N, Besozzi G, Cardascia N, Sborgia L, Niro A, Sborgia C. Acta Ophthalmol; 2009 Jun; 87(4):404-7. PubMed ID: 18782335 [Abstract] [Full Text] [Related]
10. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study. Chan WM, Lai TY, Liu DT, Lam DS. Ophthalmology; 2007 Dec; 114(12):2190-6. PubMed ID: 17599414 [Abstract] [Full Text] [Related]